新冠病毒感染診療方案第十版發布，診治方案之爭塵埃落地了嗎？_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 劉春濤

四川大學華西醫院·華西天府醫院（四川成都 610041）;

Corresponding?author：

劉春濤, Email: taosen666@vip.163.com

Keywords：

DOI：

10.7507/1671-6205.202301027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 劉春濤. 新冠病毒感染診療方案第十版發布，診治方案之爭塵埃落地了嗎？. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(1): 1-6. doi: 10.7507/1671-6205.202301027 Copy

1.	Lu G, Ling Y, Jiang MH, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in China mainland[J/OL]. Front Med. (2022-12-29) https://journal.hep.com.cn/fmd/EN/10.1007/s11684-022-0981-7.
2.	國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒肺炎診療方案 (試行第九版)[EB/OL]. http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
3.	中華醫學會呼吸病分會危重癥學組中國醫師協會呼吸醫師分會危重癥醫學專家組. 奧密克戎變異株所致重型新型冠狀病毒感染臨床救治專家推薦意見[J/OL]. 中華結核和呼吸雜志. (2023-01-04) https://rs.yiigle.com/yufabiao/1442297.htm.
4.	國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒感染診療方案 (試行第十版) [EB/OL]. (2023-01-06) http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/02ec13aadff048ffae227593a6363ee8.pdf.
5.	國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒感染重癥病例診療方案(試行第四版)[EB/OL]. (2023-01-13) http://www.nhc.gov.cn/xcs/zhengcwj/202301/ad34a9b598654b90a5c8c99440cce21b/files/754297ec20cd40eebb7fe18828d8ed31.pdf.
6.	The ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, 2022, 399(10324): 530-540.
7.	Rahmel T, Kraft F, Haberl H, et al. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. Crit Care, 2022, 26(1): 204.
8.	Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2022, 10(2): 158-166.
9.	The REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med, 2021, 384(16): 1491-1502.
10.	Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med, 2021, 9(12): 1407-1418.

1. Lu G, Ling Y, Jiang MH, et al. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in China mainland[J/OL]. Front Med. (2022-12-29) https://journal.hep.com.cn/fmd/EN/10.1007/s11684-022-0981-7.
2. 國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒肺炎診療方案 (試行第九版)[EB/OL]. http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
3. 中華醫學會呼吸病分會危重癥學組中國醫師協會呼吸醫師分會危重癥醫學專家組. 奧密克戎變異株所致重型新型冠狀病毒感染臨床救治專家推薦意見[J/OL]. 中華結核和呼吸雜志. (2023-01-04) https://rs.yiigle.com/yufabiao/1442297.htm.
4. 國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒感染診療方案 (試行第十版) [EB/OL]. (2023-01-06) http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/02ec13aadff048ffae227593a6363ee8.pdf.
5. 國家衛生健康委員會國家中醫藥管理局. 新型冠狀病毒感染重癥病例診療方案(試行第四版)[EB/OL]. (2023-01-13) http://www.nhc.gov.cn/xcs/zhengcwj/202301/ad34a9b598654b90a5c8c99440cce21b/files/754297ec20cd40eebb7fe18828d8ed31.pdf.
6. The ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, 2022, 399(10324): 530-540.
7. Rahmel T, Kraft F, Haberl H, et al. Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. Crit Care, 2022, 26(1): 204.
8. Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2022, 10(2): 158-166.
9. The REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med, 2021, 384(16): 1491-1502.
10. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med, 2021, 9(12): 1407-1418.

Next Article
Therapeutic effect of hemoperfusion for absorption of inflammatory cytokines on sepsis

Chinese Journal of Respiratory and Critical Care Medicine

新冠病毒感染診療方案第十版發布，診治方案之爭塵埃落地了嗎？

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content